Free Trial
NASDAQ:ENTX

Entera Bio (ENTX) Stock Price, News & Analysis

Entera Bio logo
$1.90 +0.01 (+0.26%)
As of 10:26 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Entera Bio Stock (NASDAQ:ENTX)

Advanced

Key Stats

Today's Range
$1.88
$1.90
50-Day Range
$1.77
$2.16
52-Week Range
$1.50
$2.79
Volume
11,797 shs
Average Volume
95,701 shs
Market Capitalization
$86.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Moderate Buy

Company Overview

Entera Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
30th Percentile Overall Score

ENTX MarketRank™: 

Entera Bio scored higher than 30% of companies evaluated by MarketBeat, and ranked 763rd out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Entera Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Entera Bio has a consensus price target of $10.00, representing about 429.1% upside from its current price of $1.89.

  • Amount of Analyst Coverage

    Entera Bio has only been the subject of 2 research reports in the past 90 days.

  • Read more about Entera Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Entera Bio are expected to decrease in the coming year, from ($0.28) to ($0.55) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Entera Bio is -7.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Entera Bio is -7.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Entera Bio has a P/B Ratio of 8.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Entera Bio's valuation and earnings.
  • Percentage of Shares Shorted

    0.10% of the outstanding shares of Entera Bio have been sold short.
  • Short Interest Ratio / Days to Cover

    Entera Bio has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Entera Bio has recently increased by 31.04%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Entera Bio does not currently pay a dividend.

  • Dividend Growth

    Entera Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.10% of the outstanding shares of Entera Bio have been sold short.
  • Short Interest Ratio / Days to Cover

    Entera Bio has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Entera Bio has recently increased by 31.04%, indicating that investor sentiment is decreasing significantly.
  • MarketBeat Follows

    Only 1 people have added Entera Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Entera Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.38% of the stock of Entera Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 14.11% of the stock of Entera Bio is held by institutions.

  • Read more about Entera Bio's insider trading history.
Receive ENTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ENTX Stock News Headlines

Your Chance Before Wall Street Moves
By the time Wall Street analysts catch on, the biggest gains are usually gone. The real profits often happen before the IPO, when private investors are buying in at a fraction of the price. Our new report, From Private to Public: How To Invest In Companies Before They IPO, shows you how to identify these deals and evaluate if they’re worth the risk.tc pixel
See More Headlines

ENTX Stock Analysis - Frequently Asked Questions

Entera Bio's stock was trading at $2.12 at the beginning of the year. Since then, ENTX stock has decreased by 10.8% and is now trading at $1.89.

Entera Bio Ltd. (NASDAQ:ENTX) announced its quarterly earnings data on Friday, August, 8th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.05. Entera Bio had a negative trailing twelve-month return on equity of 77.75% and a negative net margin of 4,525.11%.

Entera Bio (ENTX) raised $11 million in an initial public offering on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00 per share. Maxim Group acted as the underwriter for the IPO and Joseph Gunnar was co-manager.

Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Entera Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and GE Aerospace (GE).

Company Calendar

Last Earnings
8/08/2025
Today
10/07/2025
Next Earnings (Estimated)
11/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENTX
CIK
1638097
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$10.00
Potential Upside/Downside
+429.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.26)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$9.54 million
Net Margins
-4,525.11%
Pretax Margin
-6,378.31%
Return on Equity
-77.75%
Return on Assets
-68.13%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.47
Quick Ratio
10.47

Sales & Book Value

Annual Sales
$180 thousand
Price / Sales
479.43
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.23 per share
Price / Book
8.22

Miscellaneous

Outstanding Shares
45,660,000
Free Float
40,923,000
Market Cap
$86.30 million
Optionable
Optionable
Beta
1.68

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:ENTX) was last updated on 10/8/2025 by MarketBeat.com Staff
From Our Partners